

AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** An isolated polypeptide consisting ~~essentially~~ of an amino acid sequence represented by SEQ ID NO: 1.
2. **(Original)** A composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 1.
3. **(Original)** The composition of claim 2, comprising a pharmaceutically acceptable salt of the polypeptide.
4. **(Currently Amended)** The composition of claim ~~[[2]]~~ 3, wherein the pharmaceutically acceptable salt is an acetate salt.
5. **(Original)** The composition of claim 2, further comprising a pharmaceutically acceptable additive selected from the group consisting of a sugar and a surfactant.
6. **(Original)** The composition of claim 2, further comprising buffers and bulking agents.
7. **(Original)** The composition of claim 5, wherein the sugar is dextrose or mannitol.
8. **(Original)** The composition of claim 7, wherein the composition is formulated for administration with about 5% dextrose.
9. **(Original)** The composition of claim 5, wherein the surfactant is selected from the group consisting of polysorbate 20 and polysorbate 80.
10. **(Original)** The composition of claim 9, wherein the composition is formulated with from about 0.01% to about 5% surfactant.
11. **(Currently Amended)** The composition of any one of claims 2-10, wherein the composition is an ~~An immunogenic composition comprising the peptide of any one of claims 1-10.~~

12. (New) The isolated polypeptide of claim 1, wherein the polypeptide has an acetyl cap at its N-terminus, an amide cap at its C-terminus, or both.
13. (New) The composition of claim 2, wherein the polypeptide has an acetyl cap at its N-terminus, an amide cap at its C-terminus, or both.